SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Okamura, J. Articles by Enomoto, Y. Search for Related Content PubMed PubMed Citation Articles by Okamura, J. Articles by Enomoto, Y. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  A novel leukemia cell line, MR-87, with positive Philadelphia chromosome and negative breakpoint cluster region rearrangement coexpressing myeloid and early B-cell markers J Okamura, S Yamada, E Ishii, T Hara, H Takahira, J Nishimura, K Yumura, K Kawa- Ha, K Takase and Y Enomoto Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan. We developed a Philadelphia chromosome (Ph) positive cell line, designated MR-87, from a 4-year-old boy with Ph+-acute leukemia. MR-87 cells grew in single cell suspensions with a doubling time of 120 to 144 hours. Both MR-87 and original leukemia cells were positive for myeloperoxidase (MPO) and myeloid antigen CD13. These cells exhibited the early B-cell phenotype, ie, terminal deoxynucleotidyl transferase+, Ia+, CD19+, and CD10+. Rearrangement of the immunoglobulin heavy chain was confirmed in both. Approximately 80% of MR-87 cells coexpressed CD13 and lymphoid antigens CD10 or CD19, as confirmed by a two-color analysis. Simultaneous expression of MPO and CD19 on a single MR-87 cell was demonstrated at ultrastructural level. Thus, MR-87 is a Ph+ leukemia cell line exhibiting a hybrid phenotype. The breakpoint cluster region (bcr) was not rearranged in the MR-87 cells and subsequent analysis using antisera revealed that these cells expressed a novel protein, P190c-abl, which was immunoprecipitated with anti-abl and anti-phosphotyrosine antibodies. The MR-87 line will be most useful for investigating the biology and pathogenesis of Ph+ bcr- acute leukemia. Volume 72, Issue 4, pp. 1261-1268, 10/01/1988 Copyright © 1988 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Yamada, T. Murakami, T. Kaneda, M. Tadachi, M. Utsumi, S. Minami, M. Hamaguchi, M. Kasai, Y. Kodera, H. Ohashi, et al. Clinical Significance of Major and Minor bcr/abl Chimeric Transcripts in Essential Thrombocythemia Jpn. J. Clin. Oncol., November 1, 2000; 30(11): 472 - 477. [Abstract] [Full Text] [PDF]

	Copyright © 1988 by American Society of Hematology         Online ISSN: 1528-0020